• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Consumer Cyclical·AN1.AX
Share

Anagenics Limited Stocks

A$ 0.01Last Updated 20.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

A$ 3.42M

A$ 0.01
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

21.10.2026 20:13

Getty Images has filed for bankruptcy. It will become privately owned.

21.10.2026 19:00

SpaceX's strong results boosted U.S. stocks. Is the worst behind us?

21.10.2026 18:30

"The Music's Still Playing": What Wall Street Recommends Doing with Meta Shares Ahead of the Earnings Report

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026